CQS New City High Yield Fund Limited : Net Asset Value(s)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
81
CQS New City High Yield Fund Limited : Net Asset Value(s)

From:               CQS New City High Yield Fund Limited Date:                4 January 2017

Net Asset Value

The unaudited net asset value (NAV) of the Company is noted below in pence per share. NAVs are calculated in accordance with stated policies. Applicable accounting standards and AIC recommendations are followed.

The NAV per ordinary share as at the close of business on 3 January 2017 was:

  Pence per   Share Cum             Ex Income         Income  
              Basic 57.72            56.70  
   

                                                     For further information please contact:

Martin Cassels / Claire Simpson

R&H Fund Services Limited 0131 550 3760/ 3766

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FRP Holdings, Inc. Set to Announce Q3 Earnings Soon

Updated Category News Views 63

FRP Holdings, Inc. Set to Announce Q3 Earnings Soon FRP Holdings, Inc. (NASDAQ: FRPH) is gearing up for an important update regarding their financial performance. The company is set to release its earnings results for the third quarter on an upcoming Wednesday. This announcement is keenly awaited by analysts and investors alike as it reflects the company's current...

Continue Reading
ACECO's Heartwarming Initiative Distributes Backpacks for Students

Updated Category News Views 126

ACECO Partners with United Way for Community Support In a remarkable effort to support local educational needs, ACECO has engaged its Hoist Up! Outreach Committee to collaborate with the United Way for the distribution of 250 backpacks filled with school supplies. This initiative demonstrates a strong commitment to helping students thrive as they return to school....

Continue Reading
Exploring Iovance Biotherapeutics' Recent Legal Challenges

Updated Category News Views 105

An Overview of Iovance Biotherapeutics Legal Issues Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has found itself in a challenging position following a recent class-action lawsuit. This situation has arisen due to allegations of securities fraud involving the company and its senior executives. The Class Action Lawsuit Explained The lawsuit, filed by a respected securities...

Continue Reading
Ross Gerber Offers Insightful Take on Tesla and Elon Musk

Updated Category News Views 154

Ross Gerber on His Views About Tesla and Elon Musk Ross Gerber openly shares his thoughts on the dynamic leadership of Elon Musk while at the same time being critical of some of the recent directions of Tesla. During a recent episode of the 'Chasing Finance' podcast, Gerber expressed his mixed feelings stating, “I’m not a fan of Elon.” However, he quickly added,...

Continue Reading
KLA Corporation Adjusts Price Target Yet Maintains Strong Outlook

Updated Category News Views 62

Revised Price Target and Market Insights for KLA Corporation KLA Corporation (NASDAQ: KLAC) has recently seen its stock target adjusted by Stifel to $800, down from $875. Despite this revision, the firm has retained a Buy rating for the company, reflecting confidence in its performance. Stifel noted that KLA exceeded expectations in its latest quarterly performance,...

Continue Reading